
The deal includes an approved treatment for acromegaly and other pipeline candidates

Vertex has released results from its phase 1/2 trial for VX-880, a stem-cell-derived therapy that restores insulin production

A new deal will see Vertex harness Arbor Biotechnologies gene-editing technology to enhance its discovery efforts

Strong growth in women’s health and biosimilars is driving the new company, which expects 2021 growth in the “low to mid-single digit range”

Sales grew by 19% in the second quarter as key products begin to recover from the impact of the pandemic

GSK's vaccine business was up by 39% to £1.6bn thanks to the strong growth (46%) of its meningitis vaccine

Total revenue was up by 31% to $8.2bn and also increased by 24% to $15.2bn for the half year

COVID-19 vaccine generated $7.8bn in the second quarter of 2021 alone

Swiss pharma company also provided key updates on a number of drug candidates in its pipeline

Amended agreement sees Vertex take control of gene therapy programme

Vertex says VX-880 has potential to restore pancreatic islet cell function, including insulin production, in type 1 diabetes patients

Biotech agrees to separate deals for the development of gene-editing and mRNA therapies